“From cancer cures to crypto dreams, Propanc Biopharma now fuels both streams—mixing biotech power with blockchain beams.”
Propanc Biopharma (NASDAQ: PPCB), an Australian company, has announced that it has raised up to $100 million from Hexstone Capital, a family office with a focus on cryptocurrencies.
The money will assist the business in developing a digital asset treasury and moving PRP, its primary cancer treatment, closer to clinical trials.
TradingView
Propanc will get a $1 million upfront investment from the transaction, which is set up as a convertible preferred stock deal. Over the course of the following year, the remaining $99 million will be accessible, providing flexibility to fund blockchain and biotech projects.
In order to treat metastatic disease, the company will also expedite the development of PRP, an anticancer therapy based on proenzymes.
In the second half of 2026, first-in-human trials are anticipated to start, which would be a significant step towards the company’s research objectives.
The collaboration is a “transformative phase” for Propanc Biopharma, according to CEO James Nathanielsz. He said that the cryptocurrency treasury will strengthen the balance sheet and spur innovation in digital finance and cancer research.
A popular post by @lil_disruptor drew attention to the announcement
The news sparked lively discussion on X (formerly Twitter) among crypto and biotech communities.
Industry voices noted that Propanc Biopharma’s $100 million partnership with Hexstone Capital could mark a major step toward bridging blockchain finance and medical research innovation.
The market predicts that despite the announcement, PPCB shares dropped 10.5% on Nasdaq after the news and are down 46.7% over the previous month.
As the business develops, Propanc Biopharma hopes to show how integrating biotech innovations with blockchain-based financial stability may promote long-term shareholder value and sustainable growth.
You need to login in order to Like
Leave a comment